SiBone (NASDAQ:SIBN) Stock: Insider Anshul Maheshwari Sells 1,715 Shares

SiBone (NASDAQ:SIBN – Get Free Report) insider Anshul Maheshwari sold 1,715 shares of the firm’s stock in a transaction on Tuesday, November 17th. The stock was sold at an average price of $23.19, for a total value of $39,770.85. Following the completion of the transaction, the insider owned 204,870 shares in the company, valued at $4,750,935.30. This represents a 0.83% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Anshul Maheshwari also recently made the following trade(s):

  • On Monday, November 16th, Anshul Maheshwari sold 4,665 shares of SiBone stock. The shares were sold at an average price of $23.32, for a total value of $108,787.80.
  • On Wednesday, November 4th, Anshul Maheshwari sold 3,247 shares of SiBone stock. The shares were sold at an average price of $25.00, for a total value of $81,175.00.
  • On Thursday, October 29th, Anshul Maheshwari sold 3,738 shares of SiBone stock. The shares were sold at an average price of $22.50, for a total value of $84,105.00.
  • On Monday, October 5th, Anshul Maheshwari sold 1,731 shares of SiBone stock. The stock was sold at an average price of $19.50, for a total value of $33,754.50.
  • On Friday, October 2nd, Anshul Maheshwari sold 3,318 shares of SiBone stock. The stock was sold at an average price of $18.18, for a total value of $60,321.24.
  • On Monday, August 24th, Anshul Maheshwari sold 11,636 shares of SiBone stock. The stock was sold at an average price of $20.11, for a total value of $233,999.96.
  • On Friday, August 21st, Anshul Maheshwari sold 11,228 shares of SiBone stock. The shares were sold at an average price of $20.02, for a total value of $224,784.56.

SiBone Trading Up 1.6%

Shares of NASDAQ:SIBN traded up $0.38 during mid-day trading on Wednesday, reaching $23.54. The stock had a trading volume of 1,120,107 shares, compared to its average volume of 644,914. The firm has a market cap of $1.06 billion, a PE ratio of -75.93 and a beta of 0.64. The firm has a 50 day simple moving average of $20.56 and a two-hundred day simple moving average of $16.85. The company has a current ratio of 7.58, a quick ratio of 6.15 and a debt-to-equity ratio of 0.19. SiBone has a twelve month low of $11.48 and a twelve month high of $25.92.

SiBone (NASDAQ:SIBN – Get Free Report) last issued its quarterly earnings data on Monday, November 2nd. The company reported ($0.08) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.13) by $0.05. The firm had revenue of $55.70 million during the quarter, compared to analysts’ expectations of $55.31 million. SiBone had a negative net margin of 6.20% and a negative return on equity of 7.57%. On average, research analysts predict that SiBone will post -0.34 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities analysts have recently issued reports on the stock. UBS Group boosted their price target on shares of SiBone from $25.00 to $26.00 and gave the company a “buy” rating in a report on Tuesday, November 3rd. Wall Street Zen raised SiBone from a “hold” rating to a “buy” rating in a research note on Saturday, November 7th. Weiss Ratings upgraded SiBone from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, August 20th. Citigroup reiterated a “market outperform” rating on shares of SiBone in a report on Tuesday, November 3rd. Finally, TD Cowen boosted their target price on SiBone from $20.00 to $23.00 and gave the company a “buy” rating in a research note on Tuesday, November 3rd. Seven investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $25.00.

Read Our Latest Stock Analysis on SiBone

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the stock. First Light Asset Management LLC boosted its holdings in shares of SiBone by 51.8% in the second quarter. First Light Asset Management LLC now owns 8,127,985 shares of the company’s stock valued at $132,649,000 after buying an additional 2,774,795 shares during the period. Granahan Investment Management LLC raised its holdings in shares of SiBone by 97.6% during the first quarter. Granahan Investment Management LLC now owns 1,739,097 shares of the company’s stock worth $21,965,000 after acquiring an additional 858,942 shares during the period. Paradigm Capital Management Inc. NY raised its holdings in shares of SiBone by 113.3% during the first quarter. Paradigm Capital Management Inc. NY now owns 1,126,500 shares of the company’s stock worth $14,228,000 after acquiring an additional 598,300 shares during the period. Renaissance Technologies LLC lifted its position in SiBone by 101.6% in the 1st quarter. Renaissance Technologies LLC now owns 472,619 shares of the company’s stock valued at $5,969,000 after acquiring an additional 238,219 shares in the last quarter. Finally, Dimensional Fund Advisors LP lifted its position in SiBone by 41.8% in the 1st quarter. Dimensional Fund Advisors LP now owns 618,939 shares of the company’s stock valued at $7,816,000 after acquiring an additional 182,465 shares in the last quarter. Institutional investors own 98.11% of the company’s stock.

About SiBone

(Get Free Report)

SI-BONE, Inc. is a medical technology company focused on surgical solutions for conditions affecting the sacroiliac (SI) joint and related pelvic anatomy. Founded in 2008, the company develops implants and instruments used by surgeons in procedures involving the SI joint. Its products include the iFuse Implant System, a minimally invasive approach to SI joint fusion, along with related implant systems designed for SI joint and pelvic fixation procedures. SI-BONE also offers surgical instruments and training resources for healthcare professionals.

See Also

Insider Buying and Selling by Quarter for SiBone (NASDAQ:SIBN)

Receive News & Ratings for SiBone Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SiBone and related companies with MarketBeat.com's FREE daily email newsletter.